Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
24
VOR Quote, Financials, Valuation and Earnings
Last price:
$15.03
Seasonality move
:
-46.02%
Day range:
$14.40 - $15.48
52-week range:
$2.62 - $65.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.13x
Volume:
477.9K
Avg. volume:
745.5K
1-year change:
-14.5%
Market cap:
$103M
Revenue:
--
EPS (TTM):
-$381.91
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VOR
Vor Biopharma, Inc.
|
-- | -$1.00 | -- | -282.69% | $44.60 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 15.84% | -39.95% | $31.85 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
IBIO
iBio, Inc.
|
$33.3K | -$0.07 | -83.34% | -87.42% | $5.60 |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
$24.6M | -$0.32 | 18.41% | -51.46% | $6.71 |
|
SNTI
Senti Biosciences, Inc.
|
$500K | -$0.47 | -- | -29.56% | $11.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VOR
Vor Biopharma, Inc.
|
$15.05 | $44.60 | $103M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.39 | $31.85 | $4B | 10.22x | $0.00 | 0% | 3.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$327.30 | $457.00 | $43.4B | 145.01x | $0.00 | 0% | 11.76x |
|
IBIO
iBio, Inc.
|
$2.83 | $5.60 | $97.8M | -- | $0.00 | 0% | 420.73x |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
$3.64 | $6.71 | $1.9B | -- | $0.00 | 0% | 21.86x |
|
SNTI
Senti Biosciences, Inc.
|
$0.95 | $11.50 | $25M | -- | $0.00 | 0% | 3.27x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VOR
Vor Biopharma, Inc.
|
-0.14% | 23.817 | 0.92% | 9.05x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 3.124 | 1.15% | 3.40x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 0.880 | 5.64% | 2.51x |
|
IBIO
iBio, Inc.
|
4.15% | 1.951 | 4.22% | 8.94x |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
6.45% | 2.185 | 3.66% | 5.06x |
|
SNTI
Senti Biosciences, Inc.
|
78.76% | -1.416 | 81.25% | 1.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VOR
Vor Biopharma, Inc.
|
-$2K | -$28.1M | -- | -- | -- | -$53.9M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
IBIO
iBio, Inc.
|
-$241K | -$6.9M | -72.75% | -80.97% | -5951% | -$5.8M |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
$8.7M | -$108.3M | -58.45% | -63.64% | -304.84% | -$47.3M |
|
SNTI
Senti Biosciences, Inc.
|
-$904K | -$16.9M | -79.41% | -173.17% | -- | -$9.4M |
Vor Biopharma, Inc. vs. Competitors
-
Which has Higher Returns VOR or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Vor Biopharma, Inc.'s net margin of 96.33%. Vor Biopharma, Inc.'s return on equity of -- beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital VORVor Biopharma, Inc.-- -$121.63 -$2.2B ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About VOR or ACAD?
Vor Biopharma, Inc. has a consensus price target of $44.60, signalling upside risk potential of 196.35%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.85 which suggests that it could grow by 36.17%. Given that Vor Biopharma, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Vor Biopharma, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VORVor Biopharma, Inc.5 1 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is VOR or ACAD More Risky?
Vor Biopharma, Inc. has a beta of 1.989, which suggesting that the stock is 98.949% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.872%.
-
Which is a Better Dividend Stock VOR or ACAD?
Vor Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vor Biopharma, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VOR or ACAD?
Vor Biopharma, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Vor Biopharma, Inc.'s net income of -$812.7M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Vor Biopharma, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 10.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vor Biopharma, Inc. is -- versus 3.70x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VORVor Biopharma, Inc.-- -- -- -$812.7M ACADACADIA Pharmaceuticals, Inc.3.70x 10.22x $284M $273.6M
-
Which has Higher Returns VOR or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Vor Biopharma, Inc.'s net margin of 16.99%. Vor Biopharma, Inc.'s return on equity of -- beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital VORVor Biopharma, Inc.-- -$121.63 -$2.2B ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About VOR or ALNY?
Vor Biopharma, Inc. has a consensus price target of $44.60, signalling upside risk potential of 196.35%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 39.63%. Given that Vor Biopharma, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Vor Biopharma, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VORVor Biopharma, Inc.5 1 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is VOR or ALNY More Risky?
Vor Biopharma, Inc. has a beta of 1.989, which suggesting that the stock is 98.949% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.901%.
-
Which is a Better Dividend Stock VOR or ALNY?
Vor Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vor Biopharma, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VOR or ALNY?
Vor Biopharma, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Vor Biopharma, Inc.'s net income of -$812.7M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Vor Biopharma, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 145.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vor Biopharma, Inc. is -- versus 11.76x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VORVor Biopharma, Inc.-- -- -- -$812.7M ALNYAlnylam Pharmaceuticals, Inc.11.76x 145.01x $1.1B $186.4M
-
Which has Higher Returns VOR or IBIO?
iBio, Inc. has a net margin of -- compared to Vor Biopharma, Inc.'s net margin of -5720%. Vor Biopharma, Inc.'s return on equity of -- beat iBio, Inc.'s return on equity of -80.97%.
Company Gross Margin Earnings Per Share Invested Capital VORVor Biopharma, Inc.-- -$121.63 -$2.2B IBIOiBio, Inc.-189% -$0.09 $59M -
What do Analysts Say About VOR or IBIO?
Vor Biopharma, Inc. has a consensus price target of $44.60, signalling upside risk potential of 196.35%. On the other hand iBio, Inc. has an analysts' consensus of $5.60 which suggests that it could grow by 97.88%. Given that Vor Biopharma, Inc. has higher upside potential than iBio, Inc., analysts believe Vor Biopharma, Inc. is more attractive than iBio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VORVor Biopharma, Inc.5 1 0 IBIOiBio, Inc.6 0 0 -
Is VOR or IBIO More Risky?
Vor Biopharma, Inc. has a beta of 1.989, which suggesting that the stock is 98.949% more volatile than S&P 500. In comparison iBio, Inc. has a beta of 1.180, suggesting its more volatile than the S&P 500 by 17.972%.
-
Which is a Better Dividend Stock VOR or IBIO?
Vor Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vor Biopharma, Inc. pays -- of its earnings as a dividend. iBio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VOR or IBIO?
Vor Biopharma, Inc. quarterly revenues are --, which are smaller than iBio, Inc. quarterly revenues of --. Vor Biopharma, Inc.'s net income of -$812.7M is lower than iBio, Inc.'s net income of -$9M. Notably, Vor Biopharma, Inc.'s price-to-earnings ratio is -- while iBio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vor Biopharma, Inc. is -- versus 420.73x for iBio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VORVor Biopharma, Inc.-- -- -- -$812.7M IBIOiBio, Inc.420.73x -- -- -$9M
-
Which has Higher Returns VOR or RXRX?
Recursion Pharmaceuticals, Inc. has a net margin of -- compared to Vor Biopharma, Inc.'s net margin of -304.24%. Vor Biopharma, Inc.'s return on equity of -- beat Recursion Pharmaceuticals, Inc.'s return on equity of -63.64%.
Company Gross Margin Earnings Per Share Invested Capital VORVor Biopharma, Inc.-- -$121.63 -$2.2B RXRXRecursion Pharmaceuticals, Inc.24.37% -$0.21 $1.2B -
What do Analysts Say About VOR or RXRX?
Vor Biopharma, Inc. has a consensus price target of $44.60, signalling upside risk potential of 196.35%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $6.71 which suggests that it could grow by 84.46%. Given that Vor Biopharma, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe Vor Biopharma, Inc. is more attractive than Recursion Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VORVor Biopharma, Inc.5 1 0 RXRXRecursion Pharmaceuticals, Inc.1 5 0 -
Is VOR or RXRX More Risky?
Vor Biopharma, Inc. has a beta of 1.989, which suggesting that the stock is 98.949% more volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock VOR or RXRX?
Vor Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vor Biopharma, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VOR or RXRX?
Vor Biopharma, Inc. quarterly revenues are --, which are smaller than Recursion Pharmaceuticals, Inc. quarterly revenues of $35.5M. Vor Biopharma, Inc.'s net income of -$812.7M is lower than Recursion Pharmaceuticals, Inc.'s net income of -$108.1M. Notably, Vor Biopharma, Inc.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vor Biopharma, Inc. is -- versus 21.86x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VORVor Biopharma, Inc.-- -- -- -$812.7M RXRXRecursion Pharmaceuticals, Inc.21.86x -- $35.5M -$108.1M
-
Which has Higher Returns VOR or SNTI?
Senti Biosciences, Inc. has a net margin of -- compared to Vor Biopharma, Inc.'s net margin of --. Vor Biopharma, Inc.'s return on equity of -- beat Senti Biosciences, Inc.'s return on equity of -173.17%.
Company Gross Margin Earnings Per Share Invested Capital VORVor Biopharma, Inc.-- -$121.63 -$2.2B SNTISenti Biosciences, Inc.-- -$0.69 $38.2M -
What do Analysts Say About VOR or SNTI?
Vor Biopharma, Inc. has a consensus price target of $44.60, signalling upside risk potential of 196.35%. On the other hand Senti Biosciences, Inc. has an analysts' consensus of $11.50 which suggests that it could grow by 1107.48%. Given that Senti Biosciences, Inc. has higher upside potential than Vor Biopharma, Inc., analysts believe Senti Biosciences, Inc. is more attractive than Vor Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VORVor Biopharma, Inc.5 1 0 SNTISenti Biosciences, Inc.3 0 0 -
Is VOR or SNTI More Risky?
Vor Biopharma, Inc. has a beta of 1.989, which suggesting that the stock is 98.949% more volatile than S&P 500. In comparison Senti Biosciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock VOR or SNTI?
Vor Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Senti Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vor Biopharma, Inc. pays -- of its earnings as a dividend. Senti Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VOR or SNTI?
Vor Biopharma, Inc. quarterly revenues are --, which are smaller than Senti Biosciences, Inc. quarterly revenues of --. Vor Biopharma, Inc.'s net income of -$812.7M is lower than Senti Biosciences, Inc.'s net income of -$18.1M. Notably, Vor Biopharma, Inc.'s price-to-earnings ratio is -- while Senti Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vor Biopharma, Inc. is -- versus 3.27x for Senti Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VORVor Biopharma, Inc.-- -- -- -$812.7M SNTISenti Biosciences, Inc.3.27x -- -- -$18.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
93
NBTX alert for Mar 5
Nanobiotix SA [NBTX] is up 17.92% over the past day.
Sell
45
MRNA alert for Mar 5
Moderna, Inc. [MRNA] is up 16.05% over the past day.
Buy
77
SSRM alert for Mar 5
SSR Mining, Inc. [SSRM] is up 14.97% over the past day.
